Alanosine
![]() | |
![]() | |
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C3H7N3O4 |
Molar mass | 149.106 g·mol−1 |
3D model (JSmol) | |
| |
| |
Alanosine (also called SDX-102)[1] is a substance that has been studied for the treatment of pancreatic cancer.[2] It is an antimetabolite. It is used as one of a few experimental treatments for patients with deadly pancreatic cancer when the main chemotherapeutic treatment regimen of gemcitabine is no longer useful.[needs update]
References[]
- ^ PubChem. "Alanosine". pubchem.ncbi.nlm.nih.gov. Retrieved 2021-04-08.
- ^ Yu J (November 2001). "Alanosine (UCSD)". Current Opinion in Investigational Drugs. 2 (11): 1623–30. PMID 11763167.
Categories:
- Drugs not assigned an ATC code
- Antimetabolites
- Amino acid derivatives
- Nitrosamines
- Experimental drugs
- Toxic amino acids
- Antiinfective agent stubs